TNF and Obesity: The proportion of patients treated with infliximab, which in contrast to the other anti-TNF agents is dosed in a weight-dependent manner, was similar for the different BMI categories (22%, 20%, and 25% for normal weight, overweight, and obesity, respectively; overall p = 0.57).